Determination of antibody concentration as the main parameter in a dengue virus antibody-dependent enhancement assay using FcγR-expressing BHK cells

Archives of Virology

Volumn 159, Issue 1, 2014, Pages 103-116

  Moi, Meng Ling ^a   Takasaki, Tomohiko ^a   Saijo, Masayuki ^a   Kurane, Ichiro ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VIRUS;

FC RECEPTOR; VIRUS ANTIBODY;

ANIMAL; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; CELL LINE; DENGUE; DENGUE VIRUS; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; SEROLOGY; VALIDATION STUDY; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CELL LINE; CRICETINAE; DENGUE VIRUS; HUMANS; RECEPTORS, IGG; SEROLOGIC TESTS; SEVERE DENGUE;

EID: 84893801256     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-013-1787-3     Document Type: Article

References (45)

1. Colpitts TM, Rodenhuis-Zybert I, Moesker B, Wang P, Fikrig E, Smit JM (2011) prM-antibody renders immature West Nile virus infectious in vivo. J Gen Virol 92: 2281-2285.
2. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM (2010) Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 10: 712-722.
3. Han JF, Cao RY, Deng YQ, Tian X, Jiang T, Qin ED, Qin CF (2011) Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J 8: 106.
4. Meyer K, Banerjee A, Frey SE, Belshe RB, Ray R (2011) A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. PLoS One 6: e23699.
5. Takeda A, Sweet RW, Ennis FA (1990) Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and Fc gamma R. J Virol 64: 605-5610.
6. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271-283.
7. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, Yoon IK, Jarman RG, Green S, Rothman AL, Cummings DA (2010) Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis 4: e617.
8. Honda S, Saito M, Dimaano EM, Morales PA, Alonzo MT, Suarez LA, Koike N, Inoue S, Kumatori A, Matias RR, Natividad FF, Oishi K (2009) Increased phagocytosis of platelets from patients with secondary dengue virus infection by human macrophages. Am J Trop Med Hyg 80: 841-845.
9. Kurane I, Innis BL, Nisalak A, Hoke C, Nimmannitya S, Meager A, Ennis FA (1989) Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production. J Clin Invest 83: 506-513.
10. Sierra B, Perez AB, Vogt K, Garcia G, Schmolke K, Aguirre E, Alvarez M, Kern F, Kourí G, Volk HD, Guzman MG (2010) Secondary heterologous dengue infection risk: Disequilibrium between immune regulation and inflammation? Cell Immunol 262: 134-140.
11. Sun P, Bauza K, Pal S, Liang Z, Wu SJ, Beckett C, Burgess T, Porter K (2011) Infection and activation of human peripheral blood monocytes by dengue viruses through the mechanism of antibody-dependent enhancement. Virology 421: 245-252.
12. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N (2010) Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 201: 923-935.
13. Cummings DA, Irizarry RA, Huang NE, Endy TP, Nisalak A, Ungchusak K, Burke DS (2004) Travelling waves in the occurrence of dengue haemorrhagic fever in Thailand. Nature 427: 344-347.
14. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martínez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8: S7-S16.
15. Murphy BR, Whitehead SS (2011) Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29: 587-619.
16. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, Porter K, Rudiman IF, Yuwono D, Puthavathana P, Marovich MA (2008) Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 82: 3939-3951.
17. Halstead SB, Venkateshan CN, Gentry MK, Larsen LK (1984) Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. J Immunol 132: 1529-1532.
18. Kraus AA, Messer W, Haymore LB, de Silva AM (2007) Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45: 3777-3780.
19. Martin NC, Pardo J, Simmons M, Tjaden JA, Widjaja S, Marovich MA, Sun W, Porter KR, Burgess TH (2006) An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. J Virol Methods 134: 74-85.
20. Rodrigo WW, Alcena DC, Kou Z, Rose RC, Jin X, Schlesinger JJ (2009) An automated dengue virus microneutralization plaque assay performed in human Fcγ receptor-expressing CV-1 cells. Am J Trop Med Hyg 80: 61-65.
21. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS (1989) Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40: 444-451.
22. Burke DS, Kliks S (2005) Antibody-dependent enhancement in dengue virus infections. J Infect Dis 193: 601-603.
23. Green S, Libraty DH, Laoprasopwattana K, Ennis FA, Rothman AL (2006) Reply to Halstead and to Burke and Kliks. J Infect Dis 193: 603-604.
24. Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue S, Yoksan S, Luxemburger C, Lang J (2004) Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22: 3563-3574.
25. Littaua R, Kurane I, Ennis FA (1990) Human IgG Fc Receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144: 3183-3186.
26. Mady BJ, Erbe DV, Kurane I, Fanger MW, Ennis FA (1991) Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. J Immunol 147: 3139-3144.
27. Laoprasopwattana K, Libraty DH, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, Reed G, Ennis FA, Rothman AL, Green S (2005) Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 192: 510-519.
28. Morens DM, Larsen LK, Halstead SB (1987) Study of the distribution of antibody-dependent enhancement determinants on dengue 2 isolates using dengue 2-derived monoclonal antibodies. J Med Virol 22: 163-167.
29. Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I (2010) Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA. J Virol Methods 163: 205-209.
30. Ito M, Takasaki T, Kotaki A, Tajima S, Yuwono D, Rimal HS, dos Santos F, de Jesus MD, Lina BB, Tsuda Y, Lim CK, Nerome R, Calerés A, Shindo N, Drager RD, Andjaparidze A, Kurane I (2010) Molecular and virological analyses of dengue virus responsible for dengue outbreak in East Timor in 2005. Jpn J Infect Dis 63: 181-184.
31. Henchal EA, Gentry MK, McCown JM, Brandt WE (1982) Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 31: 830-836.
32. Roehrig JT, Mathews JH, Trent DW (1983) Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology 128: 118-126.
33. Yamanaka A, Kosugi S, Konishi E (2007) Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol 82: 927-937.
34. Ito M, Takasaki T, Yamada K, Nerome R, Tajima S, Kurane I (2004) Development and evaluation of fluorogenic TaqMan reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol 42: 5935-5937.
35. Ito M, Yamada K, Takasaki T, Pandey B, Nerome R, Tajima S, Morita K, Kurane I (2007) Phylogenetic analysis of dengue viruses isolated from imported dengue patients: possible aid for determining the countries where infections occurred. J Trav Med 14: 233-244.
36. Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I (2011) Detection of higher levels of dengue viremia using FcγR-expressing BHK-21 cells than FcγR-negative cells in secondary infection but not in primary infection. J Infect Dis 203: 1405-1414.
37. World Health Organization (2009) Dengue: guidelines for diagnosis, treatment, prevention and control, new edition. Geneva: World Health Organization. http://whqlibdoc. who. int/publications/2009/9789241547871_eng. pdf Accessed 27 Dec 2012.
38. Konishi E, Tabuchi Y, Yamanaka A (2010) A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. J Virol Methods 163: 360-367.
39. Moi ML, Lim CK, Tajima S, Kotaki A, Saijo M, Takasaki T, Kurane I (2011) Dengue virus isolation relying on antibody-dependent enhancement mechanism using FcγR-expressing BHK cells and a monoclonal antibody with infection-enhancing capacity. J Clin Virol 52: 225-230.
40. Morens DM, Halstead SB (1990) Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol 71: 2909-2914.
41. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS (2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1: 135-145.
42. Moi ML, Lim CK, Chua KB, Takasaki T, Kurane I (2012) Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-Expressing cells. PLoS Negl Trop Dis 6(2): e1536.
43. Moi ML, Takasaki T, Saijo M, Kurane I (2013) Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection. Trans R Soc Trop Med Hyg 107(1): 51-58.
44. Pengsaa K, Luxemburger C, Sabchareon A, Limkittikul K, Yoksan S, Chambonneau L, Chaovarind U, Sirivichayakul C, Lapphra K, Chanthavanich P, Lang J (2006) Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in Thai children. J Infect Dis 194(11): 1570-1576.
45. Halstead SB (2008) Pathogenesis: risk factors prior to infection. In: Halstead SB (ed) Dengue, 1st edn. Imperial College Prese, London, pp 226-227.